1
NSG 552 Psychopharmacology Exam 1 2 3 Wilkes
University Actual Exam 2026/2027 – Complete Exam-
Style Questions with Detailed Rationales | Pass
Guaranteed – A+ Graded
Q1: Which of the following correctly distinguishes ionotropic receptors from metabotropic
receptors?
A. Ionotropic receptors are slow-acting, G-protein coupled, while metabotropic receptors are
fast-acting ligand-gated ion channels.
B. Ionotropic receptors act via second messenger systems to open ion channels, while
metabotropic receptors directly open ion channels upon ligand binding.
C. Ionotropic receptors are ligand-gated ion channels that cause rapid synaptic transmission,
while metabotropic receptors are G-protein coupled receptors that cause slower, prolonged
effects. [CORRECT]
D. Ionotropic receptors are primarily located on the presynaptic terminal, while metabotropic
receptors are exclusively located on the postsynaptic membrane.
Correct Answer: C
Rationale: Ionotropic receptors, such as the GABA-A or NMDA receptors, are ligand-gated ion
channels that mediate fast synaptic transmission by allowing ions to flow immediately upon
neurotransmitter binding. Metabotropic receptors, such as monoamine receptors (dopamine,
serotonin), are G-protein coupled receptors (GPCRs) that activate second messenger systems,
resulting in slower but longer-lasting modulatory effects. Option A reverses the definitions.
Option B describes the mechanisms of the opposite receptor types. Option D is incorrect as both
receptor types can be found pre- and post-synaptically.
Q2: A patient is prescribed a drug that acts as a positive allosteric modulator at the GABA-A
receptor. Which of the following is the most likely mechanism of action?
A. It binds to the GABA site and directly opens the chloride channel.
B. It blocks the chloride channel, preventing inhibitory effects.
C. It binds to a site distinct from GABA, increasing the frequency of chloride channel opening
when GABA is present. [CORRECT]
,2
D. It decreases the synthesis of GABA in the presynaptic neuron.
Correct Answer: C
Rationale: Positive allosteric modulators (like benzodiazepines) bind to sites on the GABA-A
receptor complex distinct from the GABA binding site. They enhance the effect of GABA by
increasing the frequency of channel opening, allowing more chloride ions to enter the neuron,
which hyperpolarizes it and reduces neuronal excitability. Option A describes a direct agonist,
not an allosteric modulator. Option B describes an antagonist or inverse agonist. Option D refers
to synthesis inhibition, not receptor modulation.
Q3: Which neurotransmitter is primarily associated with the mesolimbic pathway and
dysfunction in this pathway is linked to positive symptoms of schizophrenia (e.g., hallucinations,
delusions)?
A. Serotonin
B. Norepinephrine
C. Dopamine [CORRECT]
D. Glutamate
Correct Answer: C
Rationale: The mesolimbic dopamine pathway projects from the ventral tegmental area to the
nucleus accumbens. Overactivity in this pathway is strongly associated with the positive
symptoms of schizophrenia (hallucinations and delusions). While serotonin and glutamate also
play roles in psychosis, dopamine is the primary neurotransmitter implicated in the mesolimbic
theory of schizophrenia. Norepinephrine is more associated with arousal and mood.
Q4: A patient taking a medication that inhibits the reuptake of serotonin experiences side effects
including nausea, sexual dysfunction, and initially increased anxiety. Which transporter is being
inhibited?
A. The dopamine transporter (DAT)
C. The serotonin transporter (SERT) [CORRECT]
D. The norepinephrine transporter (NET)
,3
Correct Answer: C
Rationale: The serotonin transporter (SERT) is responsible for the reuptake of serotonin from the
synaptic cleft back into the presynaptic neuron. Inhibiting SERT increases the concentration of
serotonin in the synapse. Common side effects of increased serotonergic activity include
gastrointestinal distress (nausea), sexual dysfunction, and initial activation/anxiety. DAT
inhibition affects dopamine (e.g., stimulants), and NET inhibition affects norepinephrine (e.g.,
SNRIs, stimulants).
Q5: Which cytochrome P450 (CYP450) enzyme is the most abundant in the liver and is
responsible for the metabolism of the widest variety of psychotropic medications?
A. CYP2D6
B. CYP1A2
C. CYP3A4 [CORRECT]
D. CYP2C19
Correct Answer: C
Rationale: CYP3A4 is the most abundant CYP enzyme in the liver and intestinal wall and is
responsible for metabolizing approximately 50% of marketed drugs, including many
benzodiazepines, antidepressants, and antipsychotics. CYP2D6 is highly polymorphic but less
abundant than CYP3A4. CYP1A2 and CYP2C19 are important but metabolize fewer substrates
compared to CYP3A4.
Q6: A patient is prescribed a drug with a half-life of 24 hours. Approximately how long will it
take to reach steady-state concentration?
A. 24 hours
B. 48 hours
C. 5 days (120 hours) [CORRECT]
D. 2 weeks
Correct Answer: C
, 4
Rationale: It takes approximately 4 to 5 half-lives for a drug to reach steady-state concentration,
where the rate of intake equals the rate of elimination. For a drug with a 24-hour half-life, steady
state is reached in 5 x 24 hours = 120 hours (5 days). Options A and B are too short; option D is
longer than necessary.
Q7: A 75-year-old patient is prescribed a highly protein-bound antipsychotic. The patient is
hypoalbuminemic due to malnutrition. What is the potential pharmacokinetic consequence?
A. Decreased free drug concentration, leading to reduced efficacy.
B. Increased free drug concentration, leading to toxicity. [CORRECT]
C. Rapid metabolism of the drug due to increased liver enzymes.
D. Decreased volume of distribution.
Correct Answer: B
Rationale: Highly protein-bound drugs (like many antipsychotics and antidepressants) bind to
albumin and alpha-1-acid glycoprotein. Only the free (unbound) drug is pharmacologically
active. In hypoalbuminemia, fewer binding sites are available, leading to a higher proportion of
free drug, which increases the risk of toxicity even if the total serum drug level appears normal.
Options A and C are opposite or unrelated effects.
Q8: Which of the following best describes the mechanism of action of Monoamine Oxidase
Inhibitors (MAOIs)?
A. Blocking the reuptake of serotonin and norepinephrine.
C. Inhibiting the enzyme that breaks down monoamine neurotransmitters (serotonin,
norepinephrine, dopamine). [CORRECT]
D. Blocking postsynaptic dopamine receptors.
Correct Answer: C
Rationale: MAOIs work by inhibiting the mitochondrial enzyme monoamine oxidase, which is
responsible for breaking down monoamine neurotransmitters (serotonin, norepinephrine, and
dopamine) in the presynaptic neuron. This inhibition increases the availability of these
neurotransmitters in the synaptic cleft. Option A describes SNRIs/TCAs. Option D describes
antipsychotics.
NSG 552 Psychopharmacology Exam 1 2 3 Wilkes
University Actual Exam 2026/2027 – Complete Exam-
Style Questions with Detailed Rationales | Pass
Guaranteed – A+ Graded
Q1: Which of the following correctly distinguishes ionotropic receptors from metabotropic
receptors?
A. Ionotropic receptors are slow-acting, G-protein coupled, while metabotropic receptors are
fast-acting ligand-gated ion channels.
B. Ionotropic receptors act via second messenger systems to open ion channels, while
metabotropic receptors directly open ion channels upon ligand binding.
C. Ionotropic receptors are ligand-gated ion channels that cause rapid synaptic transmission,
while metabotropic receptors are G-protein coupled receptors that cause slower, prolonged
effects. [CORRECT]
D. Ionotropic receptors are primarily located on the presynaptic terminal, while metabotropic
receptors are exclusively located on the postsynaptic membrane.
Correct Answer: C
Rationale: Ionotropic receptors, such as the GABA-A or NMDA receptors, are ligand-gated ion
channels that mediate fast synaptic transmission by allowing ions to flow immediately upon
neurotransmitter binding. Metabotropic receptors, such as monoamine receptors (dopamine,
serotonin), are G-protein coupled receptors (GPCRs) that activate second messenger systems,
resulting in slower but longer-lasting modulatory effects. Option A reverses the definitions.
Option B describes the mechanisms of the opposite receptor types. Option D is incorrect as both
receptor types can be found pre- and post-synaptically.
Q2: A patient is prescribed a drug that acts as a positive allosteric modulator at the GABA-A
receptor. Which of the following is the most likely mechanism of action?
A. It binds to the GABA site and directly opens the chloride channel.
B. It blocks the chloride channel, preventing inhibitory effects.
C. It binds to a site distinct from GABA, increasing the frequency of chloride channel opening
when GABA is present. [CORRECT]
,2
D. It decreases the synthesis of GABA in the presynaptic neuron.
Correct Answer: C
Rationale: Positive allosteric modulators (like benzodiazepines) bind to sites on the GABA-A
receptor complex distinct from the GABA binding site. They enhance the effect of GABA by
increasing the frequency of channel opening, allowing more chloride ions to enter the neuron,
which hyperpolarizes it and reduces neuronal excitability. Option A describes a direct agonist,
not an allosteric modulator. Option B describes an antagonist or inverse agonist. Option D refers
to synthesis inhibition, not receptor modulation.
Q3: Which neurotransmitter is primarily associated with the mesolimbic pathway and
dysfunction in this pathway is linked to positive symptoms of schizophrenia (e.g., hallucinations,
delusions)?
A. Serotonin
B. Norepinephrine
C. Dopamine [CORRECT]
D. Glutamate
Correct Answer: C
Rationale: The mesolimbic dopamine pathway projects from the ventral tegmental area to the
nucleus accumbens. Overactivity in this pathway is strongly associated with the positive
symptoms of schizophrenia (hallucinations and delusions). While serotonin and glutamate also
play roles in psychosis, dopamine is the primary neurotransmitter implicated in the mesolimbic
theory of schizophrenia. Norepinephrine is more associated with arousal and mood.
Q4: A patient taking a medication that inhibits the reuptake of serotonin experiences side effects
including nausea, sexual dysfunction, and initially increased anxiety. Which transporter is being
inhibited?
A. The dopamine transporter (DAT)
C. The serotonin transporter (SERT) [CORRECT]
D. The norepinephrine transporter (NET)
,3
Correct Answer: C
Rationale: The serotonin transporter (SERT) is responsible for the reuptake of serotonin from the
synaptic cleft back into the presynaptic neuron. Inhibiting SERT increases the concentration of
serotonin in the synapse. Common side effects of increased serotonergic activity include
gastrointestinal distress (nausea), sexual dysfunction, and initial activation/anxiety. DAT
inhibition affects dopamine (e.g., stimulants), and NET inhibition affects norepinephrine (e.g.,
SNRIs, stimulants).
Q5: Which cytochrome P450 (CYP450) enzyme is the most abundant in the liver and is
responsible for the metabolism of the widest variety of psychotropic medications?
A. CYP2D6
B. CYP1A2
C. CYP3A4 [CORRECT]
D. CYP2C19
Correct Answer: C
Rationale: CYP3A4 is the most abundant CYP enzyme in the liver and intestinal wall and is
responsible for metabolizing approximately 50% of marketed drugs, including many
benzodiazepines, antidepressants, and antipsychotics. CYP2D6 is highly polymorphic but less
abundant than CYP3A4. CYP1A2 and CYP2C19 are important but metabolize fewer substrates
compared to CYP3A4.
Q6: A patient is prescribed a drug with a half-life of 24 hours. Approximately how long will it
take to reach steady-state concentration?
A. 24 hours
B. 48 hours
C. 5 days (120 hours) [CORRECT]
D. 2 weeks
Correct Answer: C
, 4
Rationale: It takes approximately 4 to 5 half-lives for a drug to reach steady-state concentration,
where the rate of intake equals the rate of elimination. For a drug with a 24-hour half-life, steady
state is reached in 5 x 24 hours = 120 hours (5 days). Options A and B are too short; option D is
longer than necessary.
Q7: A 75-year-old patient is prescribed a highly protein-bound antipsychotic. The patient is
hypoalbuminemic due to malnutrition. What is the potential pharmacokinetic consequence?
A. Decreased free drug concentration, leading to reduced efficacy.
B. Increased free drug concentration, leading to toxicity. [CORRECT]
C. Rapid metabolism of the drug due to increased liver enzymes.
D. Decreased volume of distribution.
Correct Answer: B
Rationale: Highly protein-bound drugs (like many antipsychotics and antidepressants) bind to
albumin and alpha-1-acid glycoprotein. Only the free (unbound) drug is pharmacologically
active. In hypoalbuminemia, fewer binding sites are available, leading to a higher proportion of
free drug, which increases the risk of toxicity even if the total serum drug level appears normal.
Options A and C are opposite or unrelated effects.
Q8: Which of the following best describes the mechanism of action of Monoamine Oxidase
Inhibitors (MAOIs)?
A. Blocking the reuptake of serotonin and norepinephrine.
C. Inhibiting the enzyme that breaks down monoamine neurotransmitters (serotonin,
norepinephrine, dopamine). [CORRECT]
D. Blocking postsynaptic dopamine receptors.
Correct Answer: C
Rationale: MAOIs work by inhibiting the mitochondrial enzyme monoamine oxidase, which is
responsible for breaking down monoamine neurotransmitters (serotonin, norepinephrine, and
dopamine) in the presynaptic neuron. This inhibition increases the availability of these
neurotransmitters in the synaptic cleft. Option A describes SNRIs/TCAs. Option D describes
antipsychotics.
